Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1096 How Manage Multiple Small Bowel Neuroendocrine Tumors?

Introduction: Multiple small bowel neuroendocrine tumors (SB-NET) represent 30% of SB-NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Pasquet A

Authors: Pasquer A, Walter T, Hervieu V, Forestier J, Scoazec J,

Keywords: small bowel, surgery, prognosis, multiple,

#1081 High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?

Introduction: Thyrocalcitonin (TCT) is usually associated with medullary thyroid cancer. However, some neuroendocrine tumors (NETs) have also high serum TCT levels.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Nozière C, Chardon L, Lombard-Bohas C, Goichot B, Hervieu V,

Keywords: thyrocalcitonin,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,

#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors

Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Walter T

Authors: Benslama N, Bollard J, Vercherat C, Roche C, Hervieu V,

Keywords: neuroendocrine tumors, everolimus, markers, p-p70S6K,

#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)

Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Brakel B, Walter T, Hervieu V, Forestier J, Chayvialle J,

Keywords: MGMT,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.